Posted by Michael Wonder on 30 Jun 2021
Will Biogen’s new Alzheimer’s drug’s burden on Medicare be big, huge, or catastrophic?
28 June 2021 - The FDA’s decision to grant wide-ranging approval to the controversial, pricey new Alzheimer’s drug Aduhelm will have an eye popping impact on Medicare finances.
The question is exactly how big the impact will be.
Estimates of how many seniors on Medicare will actually take Aduhelm, which has a list price of $56,000, vary wildly. Some experts have guessed at relatively low patient interest, around 500,000 people. Biogen, the company behind the drug, has put its target population far higher, around 1 million to 2 million people.
